Tag Archive for: Kerendia

Bayer is looking to shake things up with some major company changes after reporting “not acceptable” cash flow for the third quarter on Wednesday.

Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer’s top U.S. pharmaceutical executive told Reuters.

On Monday, Bayer revealed data from a Phase III trial of Kerendia (finerenone), showing the drug’s potential to reduce the risk of all-cause and cardiovascular mortality in type 2